Hemogenyx updates on CDX antibody development
UK-based biopharma firm Hemogenyx Pharmaceuticals (LSE: HEMO) has issued an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody (CDX) for the treatment of acute myeloid leukemia (AML).
On January 13, 2021, the company announced the completion of development of CDX with an unnamed pharmaceutical company (dubbed "GlobalCo"). With the development phase of the agreement completed, GlobalCo may exercise an option to license the other party's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis, said Hemogenyx, whose shares were down 1.8% at 6.92 pence by mid-afternoon trading today.
Hemogenyx also announced that negotiations have commenced with GlobalCo regarding the form of licensing and further development of CDX toward clinical trials. The results of these negotiations and the outline of the path toward the further development of CDX will be announced upon their completion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze